<rss version="2.0"><channel><title>Yahoo! Finance: TR.TO News</title><copyright>Copyright (c) 2017 Yahoo! Inc. All rights reserved.</copyright><link>http://finance.yahoo.com/q/h?s=tr.to</link><description>Latest Financial News for TRILLIUM THERAPEUTICS INC</description><language>en-US</language><lastBuildDate>Mon, 05 Dec 2016 16:40:21 GMT</lastBuildDate><image><url>http://l.yimg.com/a/i/brand/purplelogo/uh/us/fin.gif</url><title>Yahoo! Finance: TR.TO News</title><link>http://finance.yahoo.com/q/h?s=tr.to</link><width>144</width><height>45</height></image><item><title>Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=145u9bj26/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q3-2016-by-the-numbers-december-5-2016/</link><description /><guid isPermaLink="false">yahoo_finance/3033774268</guid><pubDate>Mon, 05 Dec 2016 16:40:21 GMT</pubDate></item><item><title>Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at the American Society of Hematology Annual Meeting</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-presents-initial-data-ongoing-170000629.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented data from an ongoing study with its lead drug candidate, ...</description><guid isPermaLink="false">yahoo_finance/957973941</guid><pubDate>Sat, 03 Dec 2016 17:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Conference Call and Webcast on December 5th to Discuss TTI-621 Data Presented at ASH</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-conference-call-120000220.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host a conference call and webcast at 8:30 ...</description><guid isPermaLink="false">yahoo_finance/3181295095</guid><pubDate>Tue, 29 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128l9mrkd/*http://www.publicnow.com/view/635DD8C8783D892E9BA0FC1B12F829400CAFBB3E</link><description>[at noodls] - Additional clinical data from TTI-621 Phase 1a trial to be presented at 2016 American Society of Hematology (ASH) annual meeting in December Phase 1 trial with TTI-621 in solid tumors open for enrollment ...</description><guid isPermaLink="false">yahoo_finance/2297516602</guid><pubDate>Thu, 10 Nov 2016 12:11:07 GMT</pubDate></item><item><title>Trillium Reports Third Quarter 2016 Financial Results and Provides Corporate Update</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-third-quarter-2016-120000787.html</link><description>[Marketwired] - Trillium Therapeutics Inc. (TRIL)(TR.TO), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2016. "We established a well-tolerated dose of TTI-621 in first part of the Phase 1a/1b trial in relapsed or refractory hematologic malignancies and look forward to presenting data at next month's ASH meeting. In November, the Phase 1b dose expansion cohorts in the TTI-621 trial in patients with advanced hematologic malignancies were opened for enrollment.</description><guid isPermaLink="false">yahoo_finance/2833267355</guid><pubDate>Thu, 10 Nov 2016 12:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128s4g59i/*http://www.publicnow.com/view/600F367593083605BAA7341EA88BC10CE5404AF0</link><description>[at noodls] - TORONTO, Nov. 3, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present ...</description><guid isPermaLink="false">yahoo_finance/2405892859</guid><pubDate>Thu, 03 Nov 2016 11:07:26 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Investor and Scientific Presentation Schedule for Remainder of 2016</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-investor-scientific-110000505.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is scheduled to present an update on the company's programs and progress ...</description><guid isPermaLink="false">yahoo_finance/3480191075</guid><pubDate>Thu, 03 Nov 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Advances TTI-621 Into Phase 1B Cohort Expansion Enrollment</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128gj51k2/*http://www.publicnow.com/view/A170FD1E9DB7080A80836BDB50FB07DC575F5F3E</link><description>[at noodls] - TORONTO, Nov. 2, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel ...</description><guid isPermaLink="false">yahoo_finance/3848807346</guid><pubDate>Wed, 02 Nov 2016 11:10:10 GMT</pubDate></item><item><title>Trillium Therapeutics Advances TTI-621 Into Phase 1b Cohort Expansion Enrollment</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-advances-tti-621-110000882.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion ...</description><guid isPermaLink="false">yahoo_finance/1332910865</guid><pubDate>Wed, 02 Nov 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics, Inc. :TR-CA: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016</title><link>http://us.rd.yahoo.com/finance/external/xcapitalcube/rss/SIG=147ose7u7/*http://www.capitalcube.com/blog/index.php/trillium-therapeutics-inc-tr-ca-earnings-analysis-q2-2016-by-the-numbers-september-16-2016/</link><description /><guid isPermaLink="false">yahoo_finance/1409634109</guid><pubDate>Fri, 16 Sep 2016 16:41:44 GMT</pubDate></item><item><title>Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-introduces-industry-postdoctoral-110000999.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company has established an industry postdoctoral ...</description><guid isPermaLink="false">yahoo_finance/3273511851</guid><pubDate>Wed, 31 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Introduces Industry Postdoctoral Fellowship Program</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283bon7s/*http://www.publicnow.com/view/0CDDBDB90A821A609779D3C871295010A163F26A</link><description>[at noodls] - Toronto, Ontario, August 31, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...</description><guid isPermaLink="false">yahoo_finance/4247710028</guid><pubDate>Tue, 30 Aug 2016 19:53:02 GMT</pubDate></item><item><title>Trillium Therapeutics to Present at Investor and Scientific Conferences in September</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128krum2b/*http://www.publicnow.com/view/CE83C1926A8073643E0B662295F811F5C5EF48F1</link><description>[at noodls] - Toronto, Ontario, August 23, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...</description><guid isPermaLink="false">yahoo_finance/2534487299</guid><pubDate>Tue, 23 Aug 2016 11:18:06 GMT</pubDate></item><item><title>Trillium Therapeutics to Present at Investor and Scientific Conferences in September</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-present-investor-scientific-110000254.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on ...</description><guid isPermaLink="false">yahoo_finance/2195596355</guid><pubDate>Tue, 23 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Receives FDA Clearance to Proceed with TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=1283rpj20/*http://www.publicnow.com/view/578E365BE972DF950BC4353E7BBB210A4BB433E0</link><description>[at noodls] - Toronto, Ontario, August 17, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today ...</description><guid isPermaLink="false">yahoo_finance/3211463728</guid><pubDate>Wed, 17 Aug 2016 11:11:05 GMT</pubDate></item><item><title>Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-receives-fda-clearance-110000353.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food and Drug Administration has provided ...</description><guid isPermaLink="false">yahoo_finance/1148880496</guid><pubDate>Wed, 17 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Reports Second Quarter 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128urar7h/*http://www.publicnow.com/view/5840C4FD65ED74FF2FFC47ECC11CB6CF81C674F3</link><description>[at noodls] - On track to report clinical data from TTI-621 program at the end of 2016 IND submitted to initiate a Phase 1 trial with TTI-621 in solid tumors Cash amounted to $60.1 million (CDN) as of June 30, 2016 ...</description><guid isPermaLink="false">yahoo_finance/1816664069</guid><pubDate>Fri, 12 Aug 2016 11:21:04 GMT</pubDate></item><item><title>Trillium Reports Second Quarter 2016 Financial Results</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-reports-second-quarter-2016-110000958.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the ...</description><guid isPermaLink="false">yahoo_finance/1347405217</guid><pubDate>Fri, 12 Aug 2016 11:00:00 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress</title><link>http://us.rd.yahoo.com/finance/external/noodlsaunz/rss/SIG=128827j93/*http://www.publicnow.com/view/A01EAC28CC44842C0C6024D9A0FBAB6E2BF8FBE9</link><description>[at noodls] - Toronto, Ontario, June 7, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its ...</description><guid isPermaLink="false">yahoo_finance/2381990304</guid><pubDate>Tue, 07 Jun 2016 11:18:07 GMT</pubDate></item><item><title>Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at European Hematology Association 21st Annual Congress</title><link>http://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/news/trillium-therapeutics-announces-presentation-tti-110000757.html</link><description>[Marketwired] - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 immune checkpoint inhibitor program at the European ...</description><guid isPermaLink="false">yahoo_finance/1446724680</guid><pubDate>Tue, 07 Jun 2016 11:00:00 GMT</pubDate></item></channel></rss>